Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

Can liver cirrhosis be partially cured?

Can liver cirrhosis be partially cured?

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Case report on a shining significance in living donor transplantation

Case report on a shining significance in living donor transplantation

FDA fast tracks ViroPharma's treatment of hepatitis C

FDA fast tracks ViroPharma's treatment of hepatitis C

When HIV and liver disease co-exist

When HIV and liver disease co-exist

A cure for Hepatitis C using existing treatments

A cure for Hepatitis C using existing treatments

Cure for hepatitis C

Cure for hepatitis C

Peregrine Pharmaceuticals to initiate new Bavituximab HCV trial

Peregrine Pharmaceuticals to initiate new Bavituximab HCV trial

New test for liver disease

New test for liver disease

Liver center leading record number of studies to tackle hepatitis C

Liver center leading record number of studies to tackle hepatitis C

Rabies kills three despite proven experimental treatment

Rabies kills three despite proven experimental treatment

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences reports results of phase 2b trial of Albuferon

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Schering-Plough commits to chronic hepatitis C research

Schering-Plough commits to chronic hepatitis C research

Antipodean Pharma commences phase 2 trial in hepatitis C

Antipodean Pharma commences phase 2 trial in hepatitis C

Liver damage can be reversed

Liver damage can be reversed

Treatments used for SARS no benefit to victims

Treatments used for SARS no benefit to victims

SARS: Systematic review of treatment effects

SARS: Systematic review of treatment effects

Racial differences in hepatitis C viral responses

Racial differences in hepatitis C viral responses